Remegen

IPO

Remegen is a biotech company in Yantai, China, founded in 2008. It has raised $100.0M across 1 round, most recently a $100.0M Private Equity in March 2020.

荣昌生物制药(烟台)股份有限公司_荣昌生物

Headquarters
Yantai
Founded
2008
Business Model
B2B
Website
remegen.cn
Total Funding
$100.0M
Last Round
$100.0M Private EquityMar 2020
Rounds
1
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.

About

RemeGen Co., Ltd. was jointly founded in 2008 by Yantai Rongchang Pharmaceutical, led by Wang Weidong, and US-trained scientist Dr. Fang Jianmin. Headquartered in Yantai, Shandong, China, the company operates research institutes and offices in both China and the United States. RemeGen develops and commercializes innovative biologics, including telitacicept, described as the world's first dual-target biologic for systemic lupus erythematosus, and disitamab vedotin, described as China's first independently developed antibody-drug conjugate. The company is listed as 688331.SH on the STAR Market and 09995.HK in Hong Kong and states a mission to defeat major diseases and enhance quality of life.

Summary

It has raised $100.0M in total across 1 round, most recently a $100.0M Private Equity round in Mar 2020. Investors include Lilly Asia Ventures and Lake Bleu Capital.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPOMar 2021
$412.0M

Sign up to see all 2 events

Funding: Private Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Remegen on Indexed.vc
<a href="https://indexed.vc/companies/remegen"><img src="https://indexed.vc/api/badge/company/remegen" alt="Remegen on Indexed.vc" width="260" height="76" /></a>